Precision Medicine

A novel AI-designed drug that can cross the formidable blood-brain barrier has entered U.S. trials, targeting some of the deadliest brain tumors.

Aptorum Group is transforming into Niki BioSolutions after its merger with DiamiR, betting its future on innovative microRNA blood tests for brain health.

EHE Health is now offering GRAIL's Galleri test, a move that signals a major shift in corporate wellness but raises key questions about cost and access.

A new biotech collaboration aims to accelerate a novel diagnostic platform, highlighting a growing trend of outsourcing operations to speed innovation in precision medicine.

A groundbreaking NEJM report shows Neutrolis's therapy rapidly reversed severe Lupus symptoms, validating a new, non-immunosuppressive approach.

Parse Biosciences, QIAGEN's strategic acquisition, just partnered with Australia's Garvan Institute. It's more than science—it's a calculated play to win.

A new partnership between Nouveau Biosciences and Anova aims to fast-track a novel nanomedicine, offering a beacon of hope for patients with aggressive lymphomas.

Bruker's acquisition of the DISQVER® platform signals a major shift in infection diagnostics, promising to identify thousands of pathogens in hours, not days.

Proteomics firm Genopore hires a proven growth architect, Rey Mali. Can her commercial savvy finally democratize protein sequencing and capture a $60B market?

A new Long Island spine center isn't just offering advanced surgery; it's pioneering a 'boutique' model that merges high-tech robotics with high-touch service, rewriting the rules for patient care.

The launch of LacP™ isn't just a new test; it's a strategic move into the high-growth femtech diagnostics space, shifting the focus from reaction to prevention.

Kura Oncology's upcoming kidney cancer data is just the tip of the iceberg. A closer look reveals a strategic play to make darlifarnib a universal partner drug.

A new $4,000-a-year service combines genomics and AI for proactive health. But as SONATA launches, it exposes the deep divide in our digital future.

Atrium Therapeutics' clinical trial for a rare cardiomyopathy isn't just a milestone; it's a strategic maneuver signaling the arrival of precision RNA therapies in cardiology.

Erasca secures $550M to advance its attack on the notorious RAS/MAPK pathway. A look at the science, the strategy, and what it means for oncology.

An 82-year-old's walk across England isn't just a story of hope; it's a strategic push for a controversial protocol and a new market in cognitive health.

Alto Neuroscience's $100M raise fuels its quest to treat resistant depression. It's a high-stakes play on a biomarker-driven approach in a challenging field.

A Utah biotech is deploying UAE genomics and a novel drug to mimic natural immunity to Alzheimer's, signaling a strategic shift to precision prevention.

Elephas Biosciences adds legendary oncologist Dr. Skip Burris to its board, a pivotal move to commercialize a platform that predicts immunotherapy success.

CEO CarolAnn Tutera's recent accolade signals a mainstream shift. We decode the market strategy and regulatory landscape of her hormone therapy enterprise.